Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Product Development

Novartis’ new page prioritizes ‘high-value’ multibillion dollar assets

Narasimhan’s restructuring reunites oncology with rest of pharma, creates new role of chief strategy & growth officer

April 4, 2022 5:28 PM UTC
Updated on Apr 4, 2022 at 8:37 PM UTC

In its latest reorganization, Novartis intends to prioritize pharmaceutical products with multibillion dollar peak sales potential, while tasking a new C-level hire to be a gatekeeper who determines which pipeline candidates will make the cut.

Novartis AG (SIX:NOVN; NYSE:NVS) is taking steps to restructure its Innovative Medicines unit, eliminating some executive positions in the process, while stressing strategic priorities around high-growth and top-selling drugs. The pharma is also reorganizing its operations side to save at least $1 billion in costs by 2024...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article

BCIQ Company Profiles

Novartis AG